key: cord-0694399-9kxpzj5m
authors: Sadoff, Jerald; Davis, Kourtney; Douoguih, Macaya
title: Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
date: 2021-04-16
journal: N Engl J Med
DOI: 10.1056/nejmc2106075
sha: 72e07675226652425b202afa24a59eb8b945eff5
doc_id: 694399
cord_uid: 9kxpzj5m

nan

lish a causal relationship between these events and the Ad26.COV2.S vaccine. CVST is a very rare health condition, 4 and thus far, events reported in recipients of the Ad26.COV2.S vaccine are occurring within the range of published background incidence (0.2 to 1.57 per 100,000 person-years). 4, 5 It is important to note that the incidence of CVST associated with low platelets is unknown and is considered by the FDA and the CDC to be extremely low. 2 Muir et al. suggested that coronavirus 2019 (Covid-19) vaccines using an adenoviral (Ad) vector platform may be related to the occurrence of thrombotic thrombocytopenia. Recent reports by Greinacher et al. and Schultz et al. (both published on April 9, 2021, at NEJM.org) concluded that vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) may lead to rare thrombotic thrombocytopenia (see references S1 and S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). The vectors and spike (S) protein inserts used in the ChAdOx1 nCoV-19 vaccine and the Ad26.COV2.S vaccine are substantially different. The Ad26.COV2.S vaccine uses a human Ad26-based vector, whereas the ChAdOx1 nCoV-19 vaccine uses a chimpanzee adenovirus-based vector (references S3 and S4). Ad26 is from Ad species D and can engage CD46 as its cellular receptor, whereas ChAdOx1 nCoV-19 is from Ad species E and uses the Coxsackie and adenovirus receptor (CAR) and possibly other molecules as its cellular receptors; these two vectors thus use different host cell receptors and are likely to have different phylogenetic and biologic characteristics. In addition, the Ad26.COV2.S vaccine transgene codes for a membrane-bound SARS-CoV-2 S protein (prefusion conformation-stabilized by two proline substitutions) that does not shed S1, most likely as a consequence of knocking out the furin cleavage site (reference S5), which is different from the unmodified S protein encoded by the ChAdOx1 nCoV-19 vaccine. Therefore, these two adenoviral vector Covid-19 vaccines may have quite different biologic effects. More evidence is needed to clarify the observation of thrombotic thrombocytopenia in persons receiving a vaccine against Covid-19.

We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public. This letter was published on April 16, 2021, at NEJM.org.

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

Joint media call: FDA & CDC to discuss Janssen COVID-19 vaccine

COVID-19 vaccinations in the United States

Cerebral venous sinus thrombosis

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ACCESS background incidence rates of embolic and thrombotic events following immunisation with COVID-19 vaccines

Correspondence Copyright © 2021 Massachusetts Medical Society